search
Back to results

Metformin Use and Clinical Pregnancy Rate in Women With Unexplained Infertility

Primary Purpose

Infertility

Status
Unknown status
Phase
Early Phase 1
Locations
Egypt
Study Type
Interventional
Intervention
Metformin
Placebo
Clomiphene Citrate
Sponsored by
Elham Raafat
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility focused on measuring metformin,unexplained infertility

Eligibility Criteria

20 Years - 35 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Age 20-35 years old.
  • BMI 20-<30
  • FSH 12 IU/L or less
  • Normal transvaginal ulterasound(normal uterus and ovaries with no congenital anomalies).
  • Patent fallopian tubes assesd by hysterosalpingogram or laparoscopy.
  • Normal semen analysis.
  • Infertile women with history of previous failed induction cycle.

Exclusion Criteria:

  • Women younger than 20 or elder than 35 years old.
  • Women with BMI equal to or more than 30.
  • Uncorrected congenital or acquired uterine anomaly.
  • Other causes of infertility rather than unexplained infertility.
  • Patient with Diabetes Mellitus.

Sites / Locations

  • Elham Raafat MohamedRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Placebo Comparator

Arm Label

Metformin Group

Placebo

Arm Description

Will receive metformin plus clomiphene citrate

Will receive placebo plus clomiphene citrate.

Outcomes

Primary Outcome Measures

Clinical pregnancy rate
Diagnosis of pregnancy by transvaginal ulterasound

Secondary Outcome Measures

Full Information

First Posted
August 13, 2018
Last Updated
March 20, 2019
Sponsor
Elham Raafat
search

1. Study Identification

Unique Protocol Identification Number
NCT03681197
Brief Title
Metformin Use and Clinical Pregnancy Rate in Women With Unexplained Infertility
Official Title
Metformin Use and Clinical Pregnancy Rate in Women With Unexplained Infertility
Study Type
Interventional

2. Study Status

Record Verification Date
March 2019
Overall Recruitment Status
Unknown status
Study Start Date
June 15, 2018 (Actual)
Primary Completion Date
April 2019 (Anticipated)
Study Completion Date
May 2019 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Elham Raafat

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
The aim of this study is to asses the effect of metformin on clinical pregnancy rate in women with unexplained infertility (randomized controlled trial). This study will be conducted in infertility clinic,Ain Shams university maternity hospital,170 women with unexplained infertility will be enrolled in this study. Statistical analysis of the data will be performed .
Detailed Description
Metformin is usually used with induction regimen in patients with PCOS as it improves ovulation rate by direct effect on ovarian tissue,Metformin will be used in combination with clomiphene citrate in women with unexplained infertility with previous failed cycle to asses its efficacy on clinical pregnancy rate. Study will be conducted in infertility clinic,Ain Shams university maternity hospital.Study population comprises women with unexplained infertility aged 20-35 years with total sample size of 170 who willbe randomized into two groups with 85 women in each group. Group A:is case group who will receive metformin plus clomiphene citrate. Group B:is control group who will receive clomiphene citrate plus placebo. Metformin will be started at time of booking and will be continued till pregnancy is confirmed in a dose of 850 mg twice daily in form of tablet. Vaginal ultrasound is done for all in day 2 to exclude presence of ovarian cyst and to identify normal appearance of ovaries,then folliculometry on day 9 followed by serial folliculometry every other day till reaching dominant follicle 18 mm or more where HCG intramuscular injection will be given in a dose of 10000 iu . serum pregnancy test will be done after 16 days. Transvaginal ulterasound will be done on day 35.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Infertility
Keywords
metformin,unexplained infertility

7. Study Design

Primary Purpose
Treatment
Study Phase
Early Phase 1
Interventional Study Model
Parallel Assignment
Masking
Participant
Masking Description
Each of the consecutive women numbers will be written on sequentially numbered opaque sealed envelope that contains the assignment code.At the time of procedure,the responsible investigator will open the envelope to reveal the assignment,and she will introduce the planned method. Monitoring and follow up will be done. After enrollment,the cases will be randomly allocated into two groups.
Allocation
Randomized
Enrollment
170 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Metformin Group
Arm Type
Active Comparator
Arm Description
Will receive metformin plus clomiphene citrate
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Will receive placebo plus clomiphene citrate.
Intervention Type
Drug
Intervention Name(s)
Metformin
Other Intervention Name(s)
glucophage
Intervention Description
Metformin 850 mg tablet will be started twice daily immediately at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
In placebo group,placebo will be strted twice daily at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
Intervention Type
Drug
Intervention Name(s)
Clomiphene Citrate
Other Intervention Name(s)
Clomid
Intervention Description
50 mg of clomiphene citrate will be given starting day 2 of menstrual cycle for 5 days
Primary Outcome Measure Information:
Title
Clinical pregnancy rate
Description
Diagnosis of pregnancy by transvaginal ulterasound
Time Frame
one cycle for each woman (28 days in average)

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
35 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: Age 20-35 years old. BMI 20-<30 FSH 12 IU/L or less Normal transvaginal ulterasound(normal uterus and ovaries with no congenital anomalies). Patent fallopian tubes assesd by hysterosalpingogram or laparoscopy. Normal semen analysis. Infertile women with history of previous failed induction cycle. Exclusion Criteria: Women younger than 20 or elder than 35 years old. Women with BMI equal to or more than 30. Uncorrected congenital or acquired uterine anomaly. Other causes of infertility rather than unexplained infertility. Patient with Diabetes Mellitus.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Elham R Mohamed
Phone
0021156230921
Email
Elhamraafat@outlook.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Sarah S Moawad, Lecturer
Organizational Affiliation
Ain Shams Maternity Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Ahmed M Bahaa Eldin, Professor
Organizational Affiliation
Ain Shams Maternity Hospital
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Hisham M Fathy, Professor
Organizational Affiliation
Ain Shams Maternity Hospital
Official's Role
Study Director
Facility Information:
Facility Name
Elham Raafat Mohamed
City
Cairo
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Elham R Mohamed
Phone
0021156230921
Email
Elhamraafat@outlook.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Metformin Use and Clinical Pregnancy Rate in Women With Unexplained Infertility

We'll reach out to this number within 24 hrs